HOME >> BIOLOGY >> NEWS
Disconnect between skin cells implicated in common skin cancer

A mutation that prevents skin cells from making normal connections with each other plays an unexpectedly early and important role in the development of the skin cancer, suggests a study published in the February 23, 2001 issue of Cell.

By altering one molecule in a skin cell-cell junction in mice researchers at the University of Chicago profoundly changed the skin and caused it to behave like a pre-cancerous condition called squamous cell carcinoma in situ. Squamous cell carcinoma is one of the two most common forms of skin cancer with more than one million cases reported in the United States each year.

"Although mutations of this molecule have been found in some types of cancer, it has generally been assumed that this was a late event following other mutations disrupting cell-cycle control," said Elaine Fuchs, Ph.D., Amgen Professor of Molecular Genetics and Cell Biology and a Howard Hughes Investigator at the University of Chicago, and lead investigator of the study.

"We discovered surprisingly, this component's loss appears to be a critical early event in the development of skin cancer," said Fuchs. "This molecule appears to be doing more than simply participating in cell-cell junctions."

The organization the skin's epidermal layer depends on cell-cell connections formed by two types of intercellular structures: adherens junctions and desmosomes. The molecule alpha-catenin plays a role in adherens junctions and connects these junctions to a dynamic structural framework in the cell, the actin cytoskeleton.

Their strategy was to breed a mouse that has had the gene for alpha-catenin removed, or knocked-out, selectively in skin cells. The mouse embryo developed normally until its skin and hair begin to develop, around the 14th day of gestation. As these specialized cells, called keratinocytes, developed they did not make adherens junctions. The alpha-catenin needed to anchor the junction was missing.

Changes in the skin of the knockout mouse wer
'"/>

Contact: Jeanne Galatzer-Levy
jgalatz@uchospitals.edu
773-702-6241
University of Chicago Medical Center
22-Feb-2001


Page: 1 2 3

Related biology news :

1. Disconnecting molecular handbrakes has drastic consequences
2. Landmark agreement between Samoa and UC Berkeley could help search for AIDS cure
3. New research suggests link between maternal diet and childhood leukemia risk
4. Fossils reveal direct link between global warming and genetic diversity in wildlife
5. Battle between bubbles might have started evolution
6. UCSD researchers are first to demonstrate molecular link between inflammation and cancer
7. New survey reveals insights into unique relationship between mothers and pediatricians
8. Study explains spatial orientation differences between sexes
9. New technique helps scientists reveal interactions between genes and drugs
10. Unique partnership between UH, FDA opens path for scientific exchange
11. Study supports association between HPV infection and head and neck cancer

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Disconnect between skin cells implicated common skin cancer

(Date:10/17/2014)... – Accurate knowledge regarding Ebola is critical and pertinent ... of hazardous global outbreak and epidemic. The Journal, ... a special issue, Ebola Virus and Public Health, to ... knowledge in this critical societal moment. , On ... Ebola for Clinicians . The primer was prepared by ...
(Date:10/17/2014)... This news release is available in German . ... for only a very few drugs. When treating overdoses, doctors ... Treatment is especially difficult if there is a combination of ... is playing and accidentally swallows his grandmother,s pills? ETH professor ... Zurich wanted to find an answer to this question. "The ...
(Date:10/16/2014)... managers have a new synthesis of recent research findings ... forests in the two states. , The Ecology ... and Washington: A Synthesis of the Relevant Biophysical Science ... report published by the U.S. Forest Service,s Pacific Northwest ... from managers for a synthesis of the large body ...
Breaking Biology News(10 mins):Emergency aid for overdoses 2Emergency aid for overdoses 3New report synthesizes best available science on management of moist mixed-conifer forests 2
(Date:10/22/2014)... -- Nuvilex, Inc. (OTCQB: NVLX) – According to the ... living with diabetes, with  that number expected to grow ... for diabetes treatments is approximately $500 billion.  ... pancreatic cancer.  Pancreatic cancer is the fourth most common ... the United States , and according to a ...
(Date:10/20/2014)... The report “Pharmacy Automation Systems Market by ... Systems, Table-top Counters) by End-user (Inpatient Pharmacy Automation, ... to 2019” analyzes and studies the major market ... Asia-Pacific, and the Rest of the World (RoW). ... spread through 300 pages and in-depth TOC on ...
(Date:10/20/2014)... PARK, Calif. , Oct. 20, 2014 /PRNewswire/ ... today that the Company has signed a Notice ... of Regenerative Medicine (CIRM), effective October 1, 2014.  ... Clinical Development payments and the release of additional ... million CIRM grant award for clinical development of ...
(Date:10/20/2014)...  GenVec, Inc. (NASDAQ: GNVC ) today announced ... its board of directors effective on October 24, 2014.   Dr. ... as its chairman from June 2006 to November 2013.  During ... Governance and Audit Committees of the board.  ... dedicated service to GenVec, and its stockholders," said Wayne ...
Breaking Biology Technology:Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 2Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 4Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4Zola P. Horovitz To Retire From GenVec Board 2
Cached News: